Overview
This Module is part of the MHRA/DIA Excellence in Pharmacovigilance training course
New safety signals may emerge at any time following product launch and must be evaluated for relative risk, medical importance, and likelihood of occurrence. This module will provide approaches to signal detection using quantitative methods illustrated in a workshop with examples as well as general considerations on signal management in the EEA.
Program Committee
-
Gaby L. Danan, MD, PhD Pharmacovigilance Expert
GLD, France -
Phil Tregunno Deputy Director - Patient Safety Monitoring
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Have an account?